Primary Aldosteronism: Superselective Embolization vs. Laparoscopic Endocrine Curative Therapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

570 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-08-01

Study Completion Date

2026-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study was to compare the efficacy and safety of adrenalectomy and superselective adrenal artery embolization in a prospective, multicenter, randomized controlled study. To provide a new interventional alternative therapy for primary aldosteronism.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Multifaceted Comparison of Ultrasound-guided Ablation and Laparoscopic Adrenalectomy for Aldosterone-producing Adenoma

NCT05991856

Aldosterone-producing Adenoma Radiofrequency Ablation

RECRUITING

Comparison of Needlescopic vs. Conventional Laparoscopic Adrenalectomy for Tumor Less Than 4 cm

NCT05675124

Post Operative Pain, Acute

NOT_YET_RECRUITING NA

Prospective Randonmized Comparison of Needlescopic Versus Conventional Laparoscopic Adrenalectomy

NCT00713115

Adrenal Tumors

UNKNOWN NA

Comparative Effectiveness of Different Surgical Approaches for Giant Pituitary Adenomas

NCT05448690

Surgery Pituitary Adenoma

COMPLETED NA

Precise Diagnosis, Treatment and Prognostic Evaluation of Complicated Adrenal Tumor Diseases

NCT04529629

Complicated Adrenal Tumor Diseases

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary hyperaldosteronism is caused by excessive aldosterone secretion caused by adrenal cortex disease, which leads to increased sodium and potassium discharge, increased fluid volume and inhibition of renin-angiotensin-aldosterone system. It is one of the common causes of secondary hypertension as clinical symptoms with hypertension, hypokalemia, hyperaldosterone and low renin. It accounts for 5% to 13% of people with hypertension. In addition to the impact of hypertension itself on the body, the endocrine hormone disorder and electrolyte imbalance associated with PA may also become independent risk factors for cardiovascular and cerebrovascular events, and the risk of stroke, atrial fibrillation and myocardial infarction is significantly higher than that of essential hypertension, so early detection and reasonable treatment are crucial. PA can be divided into 6 types according to the etiology, of which the most common is idiopathic aldosteronism (IHA) and aldosteronoma, accounting for 60% and 30% respectively, unilateral adrenal hyperplasia followed, the other subtypes are less common. Previous guidelines have recommended surgery and drug intervention as the main measures for the treatment of PA, while unilateral PA is preferred by surgery and laparoscopic adrenalectomy. However, surgical treatment also has many limitations: First, not all patients with surgical indications have the opportunity to undergo adrenal resection. Surgical treatment is not suitable for patients with difficult laparoscopic operation, such as obesity, serious abdominal adhesion due to previous surgical history, and high-risk surgery, such as cardiovascular and cerebrovascular diseases and emphysema. In addition, adrenal resection may lead to adrenal dysfunction, serious infection, retroperitoneal hematoma and many other adverse reactions. The efficacy and safety of superselective adrenal artery embolization as a new alternative therapy for PA intervention have been proved. The aim of this study was to compare the efficacy of adrenectomy and superselective adrenal artery embolization according to international PASO evaluation criteria, and to conduct a prospective, multicenter, randomized controlled study in Xinjiang to explore the potential of SAAE as a treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Aldosteronism Suprarenalectomy Super Selective Adrenal Artery Embolization

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Superselective adrenal artery embolization group

Superselective adrenal artery embolization for primary aldosteronism

Group Type EXPERIMENTAL

Superselective adrenal artery embolization or adrenalectomy

Intervention Type PROCEDURE

Arm A underwent SAAE treatment, and arm B underwent laparoscopic adrenalectomy.

Adrenalectomy group

Adrenalectomy for primary aldosteronism

Group Type ACTIVE_COMPARATOR

Superselective adrenal artery embolization or adrenalectomy

Intervention Type PROCEDURE

Arm A underwent SAAE treatment, and arm B underwent laparoscopic adrenalectomy.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Superselective adrenal artery embolization or adrenalectomy

Arm A underwent SAAE treatment, and arm B underwent laparoscopic adrenalectomy.

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Adrenalectomy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18-60
* Diagnosed with primary aldosteronism according to the 2016 Clinical guidelines of the International Endocrine Society
* Primary aldosteronism diagnosed according to international guidelines Unilateral disease by AVS or PET-CT criteria
* Patients and their family members signed informed consent and agreed to participate in the study

Exclusion Criteria

* A history of severe hypersensitivity to contrast media
* Severe liver disease complications, such as thrombocytopenia, esophageal varices rupture bleeding, etc
* Renal insufficiency (serum creatinine \> 176mmol/L or estimated glomerular filtration rate \< min.1.73m2)
* Combined with other secondary hypertension, such as pheochromocytoma, hypercortisolism, renal vascular hypertension (such as renal artery stenosis), renin secretory tumor, renal parenchymatous hypertension, drug-induced hypertension (such as long-term use of glucocorticoids, contraceptives, estrogen, herbal medicines containing glycyrrhizin), pregnancy hypertension and other secondary hypertension
* Combined with genetic diseases: such as false aldosteronism (Liddle syndrome), Bartter syndrome, familial hypokalemia and hypomagnesia (Gitelman syndrome)
* Stroke, myocardial infarction and stent implantation occurred in the past 3 months
* Serious other diseases, such as heart dysfunction (grade IV), acute infections, autoimmune diseases, various malignant tumors, etc
* Participated in other clinical trials within the past 3 months
* Pregnant, breastfeeding, or planning a pregnancy
* Identify patients with alcohol allergy

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No